Description
Clomifene (Clomiphene citrate, Clomid) is a first-generation selective estrogen receptor modulator (SERM). The substance is a mixture of two stereoisomers - Enclomifene (trans, antiestrogen) and Zuclomifene (cis, weakly estrogenic) in approximate 62:38 ratio. This mixture is important for the action profile and makes the difference from purer Enclomifene.
Per study reports Clomifene blocks estrogen receptors in the hypothalamus. This removes the negative feedback of estradiol on GnRH pulse frequency. The hypothalamus increases GnRH secretion. The result is a rise in LH and FSH from the pituitary and secondarily a rise in endogenous testosterone production in the testes.
In recreational research practice Clomifene is a main component of post-cycle therapy (PCT) after anabolic or SARM research protocols when the HPG axis has been suppressed. Typical PCT protocols use Clomifene for 4-6 weeks, often combined with Tamoxifen in the early weeks.
Known effects in studies: visual tissue sensitivity (visual phenomena like halos, floaters - usually transient), occasional mood swings, in rare cases ophthalmological effects with longer use. Pharmacokinetics: oral, half-life of about 5 days (Zuclomifene portion) and about 14 hours (Enclomifene portion).
You can order Clomifene as oral tablets in one bottle with 50mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Clomifene sits in the mid range of the risk scale. As a SERM used for decades the compound is well characterized. Its side effect profile is clearly described in the literature.
Documented in studies and the literature:
- Visual phenomena: visual tissue sensitivity such as halos and floaters is consistently documented - usually transient, with ophthalmological effects in rare cases under longer use.
- Mood swings: the Zuclomifene portion with estrogenic residual action is linked to mood effects in the literature.
- Hot flashes: described in the studies as a typical SERM effect.
- Accumulation: the long half-life of the Zuclomifene portion (about 5 days) means a slow tapering off after discontinuation.
Monitoring via bloodwork is recommended. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Outcomes of clomiphene citrate treatment in young hypogonadal men - BJU International 2011, Katz et al: Prospective study on testosterone rise and symptom response under Clomifene in young hypogonadal men.
- Clomiphene citrate is safe and effective for long-term management of hypogonadism - BJU International 2012, Moskovic et al: Long-term data on efficacy and safety over an extended use period.
- Long-Term Safety and Efficacy of Clomiphene Citrate for the Treatment of Hypogonadism - Journal of Urology 2019, Krzastek et al: Long-term safety data over multi-year use.
- Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis - Andrology 2022, Huijben et al: Systematic review documenting consistent testosterone rises and a favorable side effect profile.
